Breast cancer stem cell isolation

Methods in Molecular Biology

Volumn 1406, Issue , 2016, Pages 121-135

  Jiao, Xuanmao ^a   Rizvanov, Albert A ^a   Cristofanilli, Massimo ^a   Miftakhova, Regina R ^a   Pestell, Richard G ^a  

^a NONE

Author keywords

Breast cancer stem cells; Circulating tumor cells; Fluorescenceactivated cell sorting (FACS); Mammosphere formation; Transplantation assays

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; CD24 ANTIGEN; HERMES ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CANCER; CANCER RECURRENCE; CANCER STEM CELL; CIRCULATING TUMOR CELL; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL SEPARATION; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SEPARATION; HUMANS; MICE; NEOPLASTIC STEM CELLS;

EID: 84976248285     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3444-7_10     Document Type: Chapter

References (34)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100(7):3983–3988
2. Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J (2011) Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 64(11):937–946. doi: 10.1136/jcp.2011.090456.jcp.2011.090456 [pii]
3. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15(12):4234–4241. doi: 10.1158/1078-0432.CCR-08-1479, 1078–0432.CCR-08-1479 [pii]
4. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. doi: 10.1016/j.stem.2007.08.014, S1934-5909(07)00133-6 [pii]
5. Naor D, Sionov RV, Ish-Shalom D (1997) CD44: structure, function, and association with the malignant process. Adv Cancer Res 71:241–319
6. Zoller M (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11(4):254–267. doi: 10.1038/nrc3023, nrc3023 [pii]
7. Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R (2008) Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 14(2):181–187. doi: 10.1038/nm1703, nm1703 [pii]
8. Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ (2004) CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 64(16):5702–5711. doi: 10.1158/0008-5472.CAN-04-0389, 64/16/5702 [pii]
9. Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4(1):33–45. doi: 10.1038/nrm1004, nrm1004 [pii]
10. Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH (2010) CD24, a novel cancer biomarker, predicting disease-free survival of nonsmall cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification. J Thorac Oncol 5(5):649–657. doi: 10.1097/JTO.0b013e3181d5e554
11. Jaggupilli A, Elkord E (2012) Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012:708036. doi: 10.1155/2012/708036
12. Fang X, Zheng P, Tang J, Liu Y (2010) CD24: from A to Z. Cell Mol Immunol 7(2):100–103. doi: 10.1038/cmi.2009.119, cmi2009119 [pii]
13. Chute JP, Muramoto GG, Whitesides J, Colvin M, SafiR, Chao NJ, McDonnell DP (2006) Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A 103(31):11707–11712. doi: 10.1073/pnas.0603806103, 0603806103 [pii]
14. Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P, Josselin E, Adelaide J, Nguyen TT, Monville F, Jacquemier J, Thomassin-Piana J, Pinna G, Jalaguier A, Lambaudie E, Houvenaeghel G, Xerri L, Harel-Bellan A, Chaffanet M, Viens P, Birnbaum D (2013) ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res 73(24):7290–7300. doi: 10.1158/0008-5472.CAN-12-4704, 0008–5472.CAN-12-4704 [pii]
15. Wu S, Xue W, Huang X, Yu X, Luo M, Huang Y, Liu Y, Bi Z, Qiu X, Bai S (2015) Distinct prognostic values of ALDH1 isoenzymes in breast cancer. Tumour Biol 36(4):2421–2426. doi: 10.1007/s13277-014-2852-6
16. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64(16):5818–5824. doi: 10.1158/0008-5472.CAN-04-0754, 64/16/5818 [pii]
17. Baeuerle PA, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96(3):417–423. doi: 10.1038/sj.bjc.6603494, 6603494 [pii]
18. Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z, Hayry P, Koprowski H (1982) Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1(8275):762–765
19. Reynolds BA, Weiss S (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255(5052):1707–1710
20. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS (2003) Stem cells in normal breast development and breast cancer. Cell Prolif 36(Suppl 1):59–72, doi: 274 [pii]
21. Pastrana E, Silva-Vargas V, Doetsch F (2011) Eyes wide open: a critical review of sphere- formation as an assay for stem cells. Cell Stem Cell 8(5): 486–498. doi: 10.1016/j.stem.2011.04.007, S1934-5909(11)00172-X [pii]
22. Stingl J (2009) Detection and analysis of mammary gland stem cells. J Pathol 217(2):229–241. doi: 10.1002/path.2457
23. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bauerle T, Wallwiener M, Holland-Letz T, Hofner T, Sprick M, Scharpff M, Marme F, Sinn HP, Pantel K, Weichert W, Trumpp A (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544. doi: 10.1038/nbt.2576, nbt.2576 [pii]
24. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D, Georgoulias V (2010) Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 288(1):99–106. doi: 10.1016/j.canlet.2009.06.027, S0304-3835(09)00453-4 [pii]
25. Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8(7):545–554. doi: 10.1038/nrc2419, nrc2419 [pii]
26. Suzuki M, Mose ES, Montel V, Tarin D (2006) Dormant cancer cells retrieved from metastasisfree organs regain tumorigenic and metastatic potency. Am J Pathol 169(2):673–681. doi: 10.2353/ajpath.2006.060053, doi:S0002-9440(10)62746-0 [pii]
27. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, Shen R, Brogi E, Brivanlou AH, Giancotti FG (2012) The BMP inhibitor coco reactivates breast cancer cells at lung metastatic sites. Cell 150(4):764–779. doi: 10.1016/j.cell.2012.06.035, S0092-8674(12)00872-0[pii]
28. Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, Lisanti MP, Pestell RG (2010) c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 285(11):8218–8226. doi: 10.1074/jbc.M110.100792, M110.100792 [pii]
29. Wu K, Jiao X, Li Z, Katiyar S, Casimiro MC, Yang W, Zhang Q, Willmarth NE, Chepelev I, Crosariol M, Wei Z, Hu J, Zhao K, Pestell RG (2011) Cell fate determination factor Dachshund reprograms breast cancer stem cell function. J Biol Chem 286(3):2132–2142. doi: 10.1074/jbc.M110.148395, M110.148395 [pii]
30. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L (2008) Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10(1):R10. doi: 10.1186/bcr1855, bcr1855 [pii]
31. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM (2008) Identification of tumor-initiating cells in a p53- null mouse model of breast cancer. Cancer Res 68(12):4674–4682. doi: 10.1158/0008-5472.CAN-07-6353, 68/12/4674 [pii]
32. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE (2008) The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 68(19):7711–7717. doi: 10.1158/0008-5472.CAN-08-1949, 68/19/7711 [pii]
33. Grange C, Lanzardo S, Cavallo F, Camussi G, Bussolati B (2008) Sca-1 identifies the tumorinitiating cells in mammary tumors of BALBneuT transgenic mice. Neoplasia 10(12): 1433–1443
34. Eriksson PO, Aaltonen E, Petoral R Jr, Lauritzson P, Miyazaki H, Pietras K, Mansson S, Hansson L, Leander P, Axelsson O (2014) Novel nano-sized MR contrast agent mediates strong tumor contrast enhancement in an oncogene-driven breast cancer model. PLoS One 9(10):e107762. doi: 10.1371/journal.pone.0107762, PONE-D-14-18269 [pii]